WO2005003785A3 - Anti-inflammatory assay and compounds - Google Patents

Anti-inflammatory assay and compounds Download PDF

Info

Publication number
WO2005003785A3
WO2005003785A3 PCT/GB2004/002934 GB2004002934W WO2005003785A3 WO 2005003785 A3 WO2005003785 A3 WO 2005003785A3 GB 2004002934 W GB2004002934 W GB 2004002934W WO 2005003785 A3 WO2005003785 A3 WO 2005003785A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
inflammatory assay
inflammatory agents
mnk
inflammatory
Prior art date
Application number
PCT/GB2004/002934
Other languages
French (fr)
Other versions
WO2005003785A2 (en
Inventor
Christopher Gregory Proud
Maria Buxade Fortuny
Original Assignee
Univ Dundee
Christopher Gregory Proud
Maria Buxade Fortuny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee, Christopher Gregory Proud, Maria Buxade Fortuny filed Critical Univ Dundee
Priority to GB0602172A priority Critical patent/GB2418668B/en
Publication of WO2005003785A2 publication Critical patent/WO2005003785A2/en
Publication of WO2005003785A3 publication Critical patent/WO2005003785A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of identifying new lead anti-inflammatory agents based on the use of MNK and its action on AREBP(s) and subsequent effect on TNFcc expression is provided. The invention also relates to novel anti-inflammatory agents which disrupt MNK activity.
PCT/GB2004/002934 2003-07-03 2004-07-05 Anti-inflammatory assay and compounds WO2005003785A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0602172A GB2418668B (en) 2003-07-03 2004-07-05 Anti-inflammatory assay and compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0315587.6 2003-07-03
GBGB0315587.6A GB0315587D0 (en) 2003-07-03 2003-07-03 Anti-inflammatory assay and compounds

Publications (2)

Publication Number Publication Date
WO2005003785A2 WO2005003785A2 (en) 2005-01-13
WO2005003785A3 true WO2005003785A3 (en) 2005-03-24

Family

ID=27741521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/002934 WO2005003785A2 (en) 2003-07-03 2004-07-05 Anti-inflammatory assay and compounds

Country Status (2)

Country Link
GB (2) GB0315587D0 (en)
WO (1) WO2005003785A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2929742C (en) 2013-12-04 2022-09-20 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
JP6479854B2 (en) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ Sulfoxyimine substituted quinazolines for pharmaceutical compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IDRISS HAITHAM ET AL: "Regulation of in vitro nucleic acid strand annealing activity of heterogeneous nuclear ribonucleoprotein protein A1 by reversible phosphorylation", BIOCHEMISTRY, vol. 33, no. 37, 1994, pages 11382 - 11390, XP001204510, ISSN: 0006-2960 *
KNAUF URSULA ET AL: "Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2", MOLECULAR AND CELLULAR BIOLOGY, vol. 21, no. 16, August 2001 (2001-08-01), pages 5500 - 5511, XP002310601, ISSN: 0270-7306 *
NEININGER ARMIN ET AL: "MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 5, February 2002 (2002-02-01), pages 3065 - 3068, XP002310600, ISSN: 0021-9258 *
PYRONNET STEPHANE: "Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 60, no. 8, 2000, pages 1237 - 1243, XP002970665, ISSN: 0006-2952 *
ROUSSEAU SIMON ET AL: "Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 21, no. 23, 2 December 2002 (2002-12-02), pages 6505 - 6514, XP002310599, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
GB0315587D0 (en) 2003-08-13
GB2418668A (en) 2006-04-05
GB0602172D0 (en) 2006-03-15
GB2418668B (en) 2008-01-16
WO2005003785A2 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
WO2005000860A3 (en) Compositions and methods for treatment of disease with acetylated disaccharides
WO2004103960A3 (en) Compounds and uses thereof
WO2003080801A3 (en) Adipose stromal stem cells for tissue and vascular modification
DK1206474T3 (en) Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
TR200003036T2 (en) 12,13-Modified epothilone derivatives
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
NO20005032L (en) Treatment of parasitic diseases by inhibition of cysteine proteases by the papain superfamily
HK1073313A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2002092122A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
AU2003216542A1 (en) Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
ITMI20040798A1 (en) PROCESS AND CATALYSTS FOR THE OPENING OF NAFTENIC RINGS
AU2003215175A1 (en) Fluorescent phospholipase assay, phospholipase a2 inhibitor and stimulator, and the use thereof
AU2003290939A1 (en) Replication of biological tiussue
ATE475315T1 (en) AGENTS FOR THE BIOLOGICAL CONTROL OF FUNGAL PLANT DISEASES
WO2005003785A3 (en) Anti-inflammatory assay and compounds
AU2003249930A1 (en) Proteaseome inhibitors for the treatment of herpesviridae infected individuals
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
AU2003287099A1 (en) Extract of trapa natans and methods of using the same
WO2005023253A8 (en) Use of pde4 inhibitors for the treatment of diabetes mellitus
AU2001250571A1 (en) Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
AU2003292882A1 (en) Thrombin from venom of agkistrodon acutus used as drugs for the treatment of haemorrhage
WO2004028447A3 (en) Novel compositions and methods for the treatment of psoriasis
ITMI20032061A1 (en) SEPARATOR OF SMALL CHERRIES OR SIMILAR.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 0602172.9

Country of ref document: GB

Ref document number: 0602172

Country of ref document: GB

122 Ep: pct application non-entry in european phase